title: Sorafenib for patients with differentiated thyroid cancer.
authors.affiliation: Medical Oncology and Pharmacology, CERIA, Cochin-Port Royal Hospital, AP-HP, Paris, 75014, France. Electronic address: pascaline.boudou@cch.aphp.fr.
authors.forename: Pascaline
authors.initials: P
authors.lastname: Boudou-Rouquette
authors.affiliation: Medical Oncology and Pharmacology, CERIA, Cochin-Port Royal Hospital, AP-HP, Paris, 75014, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Thomas-Schoemann
authors.affiliation: Medical Oncology and Pharmacology, CERIA, Cochin-Port Royal Hospital, AP-HP, Paris, 75014, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Bellesoeur
authors.affiliation: Medical Oncology and Pharmacology, CERIA, Cochin-Port Royal Hospital, AP-HP, Paris, 75014, France.
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide